Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer

Carcinogenesis

Volumn 34, Issue 5, 2013, Pages 1001-1005

  Huang, Liming ^a   Wu, Chen ^a   Yu, Dianke ^a   Wang, Chengfeng ^a   Che, Xu ^a   Miao, Xiaoping ^b   Zhai, Kan ^a   Chang, Jiang ^a   Jiang, Guoliang ^c   Yang, Xianghong ^d   Cao, Guangwen ^e   Hu, Zhibin ^f   Zhou, Yongjian ^g   Zuo, Chaohui ^h   Wang, Chunyou ^b   Zhang, Xianghong ⁱ   Zhou, Yifeng ^j   Yu, Xianjun ^c   Dai, Wanjin ^d   Li, Zhaoshen ^e   Shen, Hongbing ^f   Liu, Luming ^c   Chen, Yanling ^g   Zhang, Sheng ^g   Wang, Xiaoqi ^k   Liu, Yu ^a   Sun, Menghong ^c   Cao, Wei ^d   Gao, Jun ^e   Ma, Ying ^d   Zheng, Xiongwei ^l   Cheung, Siu Tim ^k   Jia, Yongfeng ^m   Tan, Wen ^a   Wu, Tangchun ^b   Lin, Dongxin ^a   more..

^a CANCER HOSPITAL   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c FUDAN UNIVERSITY   (China)

^d CHINA MEDICAL UNIVERSITY   (China)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

^f NANJING MEDICAL UNIVERSITY   (China)

^g FUJIAN MEDICAL UNIVERSITY   (China)

^h HUNAN CANCER HOSPITAL   (China)

ⁱ HEBEI MEDICAL UNIVERSITY   (China)

^j MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^k UNIVERSITY OF HONG KONG   (Hong Kong)

^l Fujian Provincial Cancer Hospital   (China)

^m Affiliated Hospital   (Mongolia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4;

3' UNTRANSLATED REGION; ARTICLE; CANCER RISK; CONTROLLED STUDY; GENE LOCUS; GENETIC IDENTIFICATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; PANCREAS CANCER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84877129445     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt004     Document Type: Article

References (33)

1. Vincent, A. et al. (2011) Pancreatic cancer. Lancet, 378, 607-620.
2. Shi, C. et al. (2009) Familial pancreatic cancer. Arch. Pathol. Lab. Med., 133, 365-374.
3. Wu, C. et al. (2012) Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Nat. Genet., 44, 62-66.
4. Petersen, G.M. et al. (2010) A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat. Genet., 42, 224-228.
5. Amundadottir, L. et al. (2009) Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat. Genet., 41, 986-990.
6. Panagiotou, O.A. et al.; Genome-Wide Significance Project. (2012) What should the genome-wide significance threshold be? Empirical replication of borderline genetic associations. Int. J. Epidemiol., 41, 273-286.
7. Kupershmidt, I. et al. (2010) Ontology-based meta-analysis of global collections of high-throughput public data. PLoS One, 5, e13066.
8. Cavallari, I. et al. (2009) Decreased expression and promoter methylation of the menin tumor suppressor in pancreatic ductal adenocarcinoma. Genes. Chromosomes Cancer, 48, 383-396.
9. Wacholder, S. et al. (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J. Natl. Cancer Inst., 96, 434-442.
10. Xiong, F. et al. (2011) Genetic variation in an miRNA-1827 binding site in MYCL1 alters susceptibility to small-cell lung cancer. Cancer Res., 71, 5175-5181.
11. Xiong, J. et al. (2010) An estrogen receptor alpha suppressor, micro-RNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples. FEBS J., 277, 1684-1694.
12. Huang, L. et al. (2012) Copy number variation at 6q13 functions as a long-range regulator and is associated with pancreatic cancer risk. Carcinogenesis, 33, 94-100.
13. Chen, X. et al. (2008) Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk. Hum. Mol. Genet., 17, 1336-1348.
14. Venkitaraman, A.R. (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell, 108, 171-182.
15. Roy, R. et al. (2012) BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat. Rev. Cancer, 12, 68-78.
16. Naderi, A. et al. (2002) BRCA2 and pancreatic cancer. Int. J. Gastrointest. Cancer, 31, 99-106.
17. Klein, A.P. (2012) Genetic susceptibility to pancreatic cancer. Mol. Carcinog., 51, 14-24.
18. Stacey, S.N. et al.; Swedish Low-risk Colorectal Cancer Study Group. (2011) A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat. Genet., 43, 1098-1103.
19. Pickard, B.S. et al. (2008) A common variant in the 3'UTR of the GRIK4 glutamate receptor gene affects transcript abundance and protects against bipolar disorder. Proc. Natl. Acad. Sci. U.S.A., 105, 14940-14945.20.
20. Cuenda, A. (2000) Mitogen-activated protein kinase kinase 4 (MKK4). Int. J. Biochem. Cell Biol., 32, 581-587.
21. Kim, H.L. et al. (2001) Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. Cancer Res., 61, 2833-2837.
22. Nakayama, K. et al. (2006) Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol. Ther., 5, 630-634.
23. Su, G.H. et al. (1998) Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res., 58, 2339-2342.
24. Cazillis, M. et al. (2004) Disruption of MKK4 signaling reveals its tumorsuppressor role in embryonic stem cells. Oncogene, 23, 4735-4744.
25. Xin, W. et al. (2004) MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course. Clin. Cancer Res., 10, 8516-8520.
26. Wang, L. et al. (2004) Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors. Oncogene, 23, 5978-5985.
27. Cunningham, S.C. et al. (2006) Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss. Cancer Res., 66, 5560-5564.
28. Schadt, E.E. et al. (2008) Mapping the genetic architecture of gene expression in human liver. PLoS Biol., 6, e107.
29. McWilliams, R.R. et al. (2009) Polymorphic variants in hereditary pancreatic cancer genes are not associated with pancreatic cancer risk. Cancer Epidemiol. Biomarkers Prev., 18, 2549-2552.
30. Zbuk, K.M. et al. (2007) Hamartomatous polyposis syndromes. Nat. Clin. Pract. Gastroenterol. Hepatol., 4, 492-502.
31. Giardiello, F.M. et al. (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology, 119, 1447-1453.
32. de Snoo, F.A. et al. (2008) Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin. Cancer Res., 14, 7151-7157.
33. Giardiello, F.M. et al. (1993) Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut, 34, 1394-1396.